keyword
MENU ▼
Read by QxMD icon Read
search

Bioresorbable stent

keyword
https://www.readbyqxmd.com/read/29656280/real-world-bioresorbable-vascular-scaffold-experience-compared-with-second-generation-metallic-drug-eluting-stents-in-complex-coronary-lesions
#1
Naotaka Okamoto, Hiroshi Ueda, Takahiro Yoshimura, Surbhi Chamaria, Samit Bhatheja, Yuliya Vengrenyuk, Samaneh Rabiei, Yonandy Barrientos, Vishal Kapur, Nitin Barman, Joseph Sweeny, Usman Baber, Roxana Mehran, Samin K Sharma, Annapoorna S Kini
OBJECTIVES: The aim of the study was to compare the acute outcomes of Absorb bioresorbable vascular scaffolds (BVS) and second-generation drug-eluting stent (DES) implantation in routine clinical practice. There is a paucity of data regarding BVS use in a real-world patient population. METHODS: The study population comprised 40 consecutive patients who underwent percutaneous coronary intervention (PCI) with BVS implantation at a tertiary-care center in New York, New York between July and December of 2016...
April 15, 2018: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/29649071/predictors-of-early-scaffold-thrombosis-results-from-the-multicenter-prospective-german-austrian-absorb-registry
#2
Jochen Wöhrle, Holger M Nef, Christoph Naber, Stephan Achenbach, Thomas Riemer, Julinda Mehilli, Thomas Münzel, Steffen Schneider, Sinisa Markovic, Julia Seeger, Wolfgang Rottbauer, Thomas Pfannebecker, Gert Richardt, Ralf Zahn, Tommaso Gori, Johannes Kastner, Axel Schmermund, Christian W Hamm
BACKGROUND: In randomized clinical trials, the risk of thrombotic events with the absorb bioresorbable vascular scaffold (BVS) was significantly higher than with metallic drug-eluting stents. We evaluated predictors of scaffold thrombosis in the large-scale, multicenter German-Austrian ABSORB RegIstRy. METHODS AND RESULTS: 3178 patients with treatment of 4252 lesions using 5020 scaffolds were included. Follow-up rate at 6 months was 97.4%. Forty-five (1.42%) patients experienced definite/probable scaffold thrombosis during follow-up...
April 11, 2018: Coronary Artery Disease
https://www.readbyqxmd.com/read/29627111/in-stent-restenosis-of-drug-eluting-stents-compared-with-a-matched-group-of-patients-with-de-novo-coronary-artery-stenosis
#3
Kyle D Buchanan, Rebecca Torguson, Toby Rogers, Linzhi Xu, Jiaxiang Gai, Itsik Ben-Dor, William O Suddath, Lowell F Satler, Ron Waksman
Drug-eluting stents (DES) significantly reduced the incidence of in-stent restenosis (ISR). However, ISR still exists in the contemporary DES era. Previously deemed to be a benign process, ISR leads to complex presentation and intervention. This study aimed to compare the presentation and outcome of DES-ISR versus de novo lesions. We performed a retrospective analysis of 11,666 patients receiving percutaneous coronary intervention from 2003 to 2017 and divided them into 2 groups by de novo stenosis and ISR...
March 13, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29623171/bioresorbable-coronary-scaffolds-deployment-tips-and-tricks-and-the-future-of-the-technology
#4
REVIEW
J Ribamar Costa, Alexandre Abizaid
Bioresorbable scaffolds (BRS) were developed as an alternative to drug-eluting stents (DES) to facilitate vessel restoration and reduce the risk of future adverse events. However, recent meta-analyses and "real-world" registries have raised some concern about the safety of this novel technology, especially due to an increased risk of thrombosis within the first weeks of scaffold implantation. These devices appear to be less forgiving to poor implantation strategies when compared to contemporary DES...
January 2018: Methodist DeBakey Cardiovascular Journal
https://www.readbyqxmd.com/read/29622143/bioresorbable-scaffold-for-treatment-of-coronary-artery-lesions-intravascular-ultrasound-results-from-the-absorb-japan-trial
#5
Kozo Okada, Yasuhiro Honda, Hideki Kitahara, Kyuhachi Otagiri, Shigemitsu Tanaka, M Brooke Hollak, Paul G Yock, Jeffrey J Popma, Hajime Kusano, Wai-Fung Cheong, Krishnankutty Sudhir, Peter J Fitzgerald, Takeshi Kimura
OBJECTIVES: The aim of this study was to characterize post-procedural intravascular ultrasound (IVUS) findings in the ABSORB Japan trial, specifically stratified by the size of target coronary arteries. BACKGROUND: Despite overall noninferiority confirmed in recent randomized trials comparing bioresorbable vascular scaffolds (BVS) (Absorb BVS) and cobalt-chromium everolimus-eluting metallic stents (CoCr-EES), higher event rates of Absorb BVS have been reported with suboptimal deployment, especially in small coronary arteries...
April 9, 2018: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29622141/clinical-angiographic-and-procedural-correlates-of-very-late-absorb-scaffold-thrombosis-multistudy-registry-results
#6
Stephen G Ellis, Tommaso Gori, Patrick W Serruys, Holger Nef, Giuseppe Steffenino, Salvatore Brugaletta, Thomas Munzel, Cordula Feliz, Götz Schmidt, Manel Sabaté, Yoshinobu Onuma, R J van Geuns, Run-Lin Gao, Maurizio Menichelli, Dean J Kereiakes, Gregg W Stone, Luca Testa, Takeshi Kimura, Alexandre Abizaid
OBJECTIVES: The aim of this study was to identify independent correlates of very late scaffold thrombosis (VLST) from an analysis of consecutively treated patients from 15 multicenter studies. BACKGROUND: Recent analyses suggest an increased risk for VLST with the Absorb Bioresorbable Vascular Scaffold compared with drug-eluting stents, but insights as to correlates of risk are limited. METHODS: A total of 55 patients were identified with scaffold thrombosis...
April 9, 2018: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29564151/analysis-of-trends-and-prospects-regarding-stents-for-human-blood-vessels
#7
Jeong Hee Lee, Eung Do Kim, Eun Jung Jun, Hyoung Sun Yoo, Joon Woo Lee
Background: The purpose of this paper is to provide technology trends and information regarding market and prospects in stents used for human blood vessels in Korea and the world.A stent is a medical device in the form of a cylindrical metal net used to normalize flow when blood or other bodily fluids such as biliary fluids are obstructed in blood vessels, gastrointestinal tracts, etc. by inserting the stent into a narrowed or clogged area. Stents are classified into vascular and non-vascular stents...
2018: Biomaterials Research
https://www.readbyqxmd.com/read/29546748/bioresorbable-scaffolds-for-complex-coronary-interventions
#8
Maciej Lesiak, Sylwia Zawada-Iwańczyk, Magdalena Łanocha, Aneta Klotzka, Michał Lesiak
Bioresorbable scaffolds (BRS) have been introduced to clinical practice to avoid some limitations associated with the presence of permanent metal prostheses in coronary arteries. Due to elimination of the natural vasomotion of the vessel and flow disturbance, stents impair endothelial function, increasing the risk of adverse events such as late and very late thrombosis or accelerated neoatherosclerosis. Additionally, the presence of metallic stents hinders non-invasive imaging of coronaries and may exclude the possibility of bypass graft anastomosis within the stented segment...
March 15, 2018: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/29513403/absorb-bioresorbable-vascular-scaffold-vs-everolimus-eluting-metallic-stent-in-small-vessel-disease-a-propensity-matched-analysis-of-compare-ii-rai-and-maasstad-absorb-studies
#9
Giuseppe Tarantini, Giulia Masiero, Alberto Barioli, Valeria Paradies, Georgios Vlachojannis, Paola Tellaroli, Bernardo Cortese, Gaetano di Palma, Attilio Varricchio, Alfonso Ielasi, Bruno Loi, Giuseppe Steffenino, Daisuke Ueshima, Marco Mojoli, Pieter Smits
BACKGROUND: Patients with small vessel disease (SVD) are at higher risk of adverse events after PCI compared to non-SVD patients. In this subset, the use of bioresorbable vascular scaffolds (BVS) has raised particular concern. OBJECTIVE: We aimed to compare outcomes of Absorb BVS versus a 2nd-generation metallic everolimus-eluting stents (EES) in the SVD setting, by pooling patients from three large, prospective studies. METHODS: Patients with SVD (reference vessel diameter ≤2...
March 7, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29488886/quality-difference-of-neointima-following-the-implantation-of-bioresorbable-scaffold-and-metallic-stent-in-patients-with-st-elevation-myocardial-infarction-quantitative-assessments-by-light-intensity-light-attenuation-and-backscatter-on-optical-coherence-tomography
#10
Yohei Sotomi, Yoshinobu Onuma, Shengnan Liu, Taku Asano, Jeroen Eggermont, Yuki Katagiri, Rafael Cavalcante, Robbert J de Winter, Joanna J Wykrzykowska, Salvatore Brugaletta, Lorenz Räber, Manel Sabaté, Stephan Windecker, Jouke Dijkstra, Patrick W Serruys
AIMS: We aimed to assess possible difference of the neointimal quality after everolimus-eluting bioresorbable scaffold (BVS) implantation in comparison with cobalt chromium everolimus-eluting scaffold (CoCr-EES) by optical frequency domain imaging (OFDI). METHODS AND RESULTS: This study is a post-hoc analysis of TROFI II trial assessing neointimal quality 6-month after the implantation of BVS(N=82) and CoCr-EES(N=87) in STEMI patients. Neointimal light property analysis by OFDI full-automatically computed light attenuation, backscatter and light intensity for superficial and deep neointima...
February 27, 2018: EuroIntervention
https://www.readbyqxmd.com/read/29483243/strain-induced-accelerated-asymmetric-spatial-degradation-of-polymeric-vascular-scaffolds
#11
Pei-Jiang Wang, Nicola Ferralis, Claire Conway, Jeffrey C Grossman, Elazer R Edelman
Polymer-based bioresorbable scaffolds (BRS) seek to eliminate long-term complications of metal stents. However, current BRS designs bear substantially higher incidence of clinical failures, especially thrombosis, compared with metal stents. Research strategies inherited from metal stents fail to consider polymer microstructures and dynamics--issues critical to BRS. Using Raman spectroscopy, we demonstrate microstructural heterogeneities within polymeric scaffolds arising from integrated strain during fabrication and implantation...
February 26, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29455763/low-major-adverse-cardiac-event-rates-following-bioresorbable-vascular-scaffold-implantation-impact-of-implantation-technique-on-treatment-outcomes
#12
Anne Venkata Ganeshkumar, Rushikesh Sambhaji Patil, Irfan Khan Hamid
BACKGROUND AND OBJECTIVE: Studies conducted across the world have reported that the rates of major adverse cardiac events (MACE) following the use of bioresorbable vascular scaffolds (BVS) are comparable to that noted with traditional drug eluting stents (DES). However, there is limited data on the immediate and medium-term clinical outcomes following the use of the Absorb BVS (Abbott Vascular, Santa Clara, SA) in the Indian context. This study was conducted to determine real-world evidence on the immediate and medium-term clinical outcomes in all patients undergoing percutaneous coronary intervention (PCI) with the Absorb BVS...
January 2018: Indian Heart Journal
https://www.readbyqxmd.com/read/29447787/rationale-and-design-of-the-comparison-between-a-p2y12-inhibitor-monotherapy-versus-dual-antiplatelet-therapy-in-patients-undergoing-implantation-of-coronary-drug-eluting-stents-smart-choice-a-prospective-multicenter-randomized-trial
#13
Young Bin Song, Seok Kyu Oh, Ju-Hyeon Oh, Eul-Soon Im, Deok-Kyu Cho, Byung Ryul Cho, Jong-Young Lee, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuck Choi, Sang Hoon Lee, Hyeon-Cheol Gwon, Joo-Yong Hahn
BACKGROUND AND RATIONALE: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. It is unclear whether P2Y12 inhibitor monotherapy might maintain anti-ischemic efficacy while reducing the bleeding risk compared with DAPT after implantation of the current generation of drug-eluting stents (DES)...
March 2018: American Heart Journal
https://www.readbyqxmd.com/read/29435779/therapeutic-options-for-in-stent-restenosis
#14
REVIEW
Charles Nicolais, Vladimir Lakhter, Hafeez Ul Hassan Virk, Partha Sardar, Chirag Bavishi, Brian O'Murchu, Saurav Chatterjee
PURPOSE OF REVIEW: In-stent restenosis (ISR) is a complex disease process that became apparent shortly after the introduction of stents into clinical practice. This review seeks to define in-stent restenosis (ISR) as well as to summarize the major treatment options that have been developed and studied over the past two decades. RECENT FINDINGS: Recent developments in drug-coated balloons and bioresorbable vascular scaffolds have added new potential treatments for ISR...
February 12, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29426631/outcomes-of-a-novel-thin-strut-bioresorbable-polymer-sirolimus-eluting-stent-in-patients-with-chronic-total-occlusions-a-multicenter-registry
#15
Lorenzo Azzalini, Ozan M Demir, Gabriele L Gasparini, Luca Grancini, Alessio La Manna, Soledad Ojeda, Susanna Benincasa, Barbara Bellini, Enrico Poletti, Davide Maccagni, Margherita Soldi, Loredana Iannetta, Daniela Trabattoni, Giacomo Gravina, Francisco Hidalgo, Francesco Giannini, Manuel Pan, Corrado Tamburino, Antonio L Bartorelli, Bernhard Reimers, Cosmo Godino, Mauro Carlino, Antonio Colombo
BACKGROUND: We aimed to evaluate the mid-term outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent (BP-SES) in chronic total occlusion (CTO) percutaneous coronary intervention (PCI), as compared with durable-polymer everolimus-eluting stents (EES). METHODS: We compiled a multicenter registry of patients undergoing CTO recanalization followed by BP-SES or EES implantation. The primary endpoint was the incidence of target-lesion failure (TLF, a composite of cardiac death, target-vessel myocardial infarction, and target-lesion revascularization) at one year...
January 31, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29415486/impact-of-psp-technique-on-clinical-outcomes-following-bioresorbable-scaffolds-implantation
#16
REVIEW
Luis Ortega-Paz, Salvatore Brugaletta, Manel Sabaté
Bioresorbable scaffolds (BRS) were introduced in clinical practice to overcome the long-term limitations of newer-generation drug-eluting stents. Despite some initial promising results of the Absorb BRS, safety concerns have led to the discontinuation of the commercialization of this device. Several retrospective studies have assessed the impact of the so-called Pre-dilation, Sizing and Post-dilation (PSP) technique concluding that an optimal PSP technique can improve clinical outcomes following BRS implantation...
February 6, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29413240/a-randomized-trial-comparing-the-neovas-sirolimus-eluting-bioresorbable-scaffold-and-metallic-everolimus-eluting-stents
#17
Yaling Han, Bo Xu, Guosheng Fu, Xiaozeng Wang, Kai Xu, Chongying Jin, Ling Tao, Lang Li, Yuqing Hou, Xi Su, Quan Fang, Lianglong Chen, Huiliang Liu, Bin Wang, Zuyi Yuan, Chuanyu Gao, Shenghua Zhou, Zhongwei Sun, Yanyan Zhao, Changdong Guan, Gregg W Stone
OBJECTIVES: The authors sought to evaluate the safety and effectiveness of the NeoVas bioresorbable scaffold (BRS) compared with metallic drug-eluting stents. BACKGROUND: BRS have the potential to improve very late outcomes compared with metallic drug-eluting stents, but some BRS have been associated with increased rates of device thrombosis before complete bioresorption. NeoVas is a new poly-l-lactic acid BRS that elutes sirolimus from a poly-D, l-lactide coating...
February 12, 2018: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29399773/deciphering-bioresorbable-stent-thrombosis-investigating-the-mechanisms
#18
Nicholas G Kounis, Grigorios Tsigkas, Ioanna Koniari, George Tzanis, Stefanos Despotopoulos, Anastasios Roumeliotis, George Hahalis
No abstract text is available yet for this article.
2018: Kardiologia Polska
https://www.readbyqxmd.com/read/29398632/transradial-experience-with-bioresorbable-vascular-scaffolds-a-case-matched-study-with-metallic-drug-eluting-stents
#19
Frédéric Maes, Olivier Costerousse, Tomas Cieza, Mélaine Henry, Jean-Pierre Déry, Gérald Barbeau, Robert Delarochellière, Jean-Michel Paradis, Eric Larose, Can M Nguyen, Charles Pirlet, Rosaire Mongrain, Olivier F Bertrand
BACKGROUND: Whether polymeric bioresorbable vascular scaffolds (BVS) implantation with transradial approach is feasible and safe is unknown. We compared the feasibility and safety of the transradial approach for BVS delivery with metallic drug-eluting stents (DES). METHODS: We identified 118 consecutive patients who underwent BVS implantation and we compared 30-days and 1-year results with 118 matched patients with DES. Patients were matched for age, sex, risk factors and clinical indication...
January 6, 2018: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/29372810/treatment-of-coronary-bifurcation-lesions-current-knowledge-and-future-perspectives
#20
Mostafa Elwany, Gaetano Di Palma, Bernardo Cortese
Coronary lesions at bifurcation sites are frequent and still remain a challenging subset for the interventional cardiologist. Although in the last years the provisional stenting technique has shown more consistent results, coronary bifurcation interventions still share a worse procedural success rate and increased rates of mid- and long-term cardiac events. Most of the dedicated devices proposed in the last few years have failed to show improved results when compared with standard devices. The broader use of imaging techniques, such as intravascular ultrasound and optical coherence tomography, lead to a better understanding of the real anatomy of bifurcations and has shown to be a great tool for percutaneous coronary intervention optimization...
January 26, 2018: Future Cardiology
keyword
keyword
116611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"